In patients with moderate-to-severe allergic asthma, tezepelumab yields the greatest reduction in exacerbations among biologics compared with placebo.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tezepelumab-best-reducing-exacerbations-patients-moderate-2025a1000v22?src=rss
Author :
Publish date : 2025-11-10 07:15:00
Copyright for syndicated content belongs to the linked Source.
